| MS animal model | Method | Results | References |
| EAE (PLP/SJL) | GSI | ↓Disease, ↓Th1 | Minter et al., 2005 [10] | EAE (PLP/SJL) | Anti-Notch3 | ↓Disease, ↓Th1, and ↓Th17 | Jurynczyk et al., 2008 [32] | EAE (PLP/SJL) | GSI | ↓Disease, ↓Th17 | Keerthivasan et al., 2011 [31] | EAE (MOG/B6) | Anti-Dll1 | ↓Disease, ↓Th1 | Elyaman et al., 2007 [35] | TMEV-IDD | Anti-Dll1 | ↓Disease, ↓IFN-, and ↓IL-4 | Tsugane et al., 2012 [36] | TMEV-IDD | Anti-Dll4 | ↓Disease, ↓IFN-, and ↓IL-17 | Takeichi et al., 2010 [37] | EAE (PLP/SJL) | Anti-Dll4 | ↓Disease, ↓Th1, and ↓Th17 | Reynolds et al., 2011 [38] | EAE (MOG/B6) | Anti-Dll4 | ↓Disease, ↓Th1, ↓Th17, ↑Th2, and ↑Treg | Bassil et al., 2011 [13] | EAE (MOG/B6) | Anti-Jagged1 | ↑Disease, ↓IL-10 | Elyaman et al., 2007 [35] | EAE (MOG/B6) | Jagged1 peptide | ↓Disease, ↓IFN-, and ↑IL-4 | Palacios et al., 2007 [39] | EAE (MOG/B6) | Anti-Jagged2 signaling molecules prior to immunization | ↓Disease, ↑Treg |
Elyaman et al., 2012 [21] | Anti-Jagged2 signaling molecules at time of immunization | ↑Disease, ↑IL-17 |
|
|